DIGITAL BIOLOGY
Features
Enveda raises $311 million Series E after two positive early clinical readouts
Catalio Capital Management led the round, which brings Enveda's total capital raised since inception to more than $845 million. Enveda reports that in a Phase 1b study, ENV-294 improved eczema severity by an average of 85% after 42 days with no serious side effects, and that ENV-308 was well tolerated in 88 healthy volunteers. Proceeds will fund later-stage trials for both candidates and a third, ENV-6946, now in Phase 1.
Genentech partners with Earendil Labs to discover bispecific antibodies in oncology
Earendil Labs will lead antibody discovery and research through early clinical development for multiple bispecific antibody programs, with Genentech, a member of the Roche Group, responsible for later global development and commercialization. Earendil will receive a $55 million upfront payment, is eligible for tiered royalties on net sales, and the collaboration's total potential value, including development, regulatory and sales milestones, exceeds $1.5 billion.
AbbVie partners with Iambic to apply AI models to small-molecule drug discovery
The multi-year collaboration spans immunology, neuroscience and oncology and will use Enchant v3, Iambic's next-generation multimodal transformer trained on over 6,000 molecular properties, which Iambic says is designed to achieve industry-leading prediction accuracy. Iambic will receive an upfront payment plus milestone payments and tiered royalties; financial terms were not otherwise disclosed.
Basecamp Research raises $140 million Series C to advance AI-designed therapeutics toward clinic
S32 led the oversubscribed round, with participation from NVIDIA, Menlo Ventures' Anthology Fund and other investors, to train a new generation of Basecamp's EDEN foundation models. The funding will start with in vivo cell therapy, pairing EDEN's DNA-sequence design with large serine recombinases for genome integration. Basecamp says it has demonstrated strong preclinical results across multiple modalities and disease areas, though the therapeutics remain in preclinical development.
Deep Origin deploys in silico drug safety models to four pilot organizations
Deep Origin's ARPA-H-funded PREDICTS consortium has put 62 of 77 in-development ADMET models into partners' hands, who are screening millions of compounds to prioritize drug candidates. Partner organizations will send their wet-lab results back to extend the training data, and Deep Origin reports that 89% of the 62 models released so far outperform the best-performing model it identified in the literature.